Soleno Therapeutics Inc financial data

Symbol
SLNO on Nasdaq
Location
100 Marine Parkway, Suite 400, Redwood City, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.67K % +64.1%
Debt-to-equity 30.1 % +62.2%
Return On Equity -73.7 % -70.5%
Return On Assets -56.7 % -55.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.1M shares +36.7%
Common Stock, Shares, Outstanding 50.4M shares +31.4%
Entity Public Float 1.4B USD +4130%
Common Stock, Value, Issued 50K USD +31.6%
Weighted Average Number of Shares Outstanding, Basic 50.5M shares +30.7%
Weighted Average Number of Shares Outstanding, Diluted 50.5M shares +30.7%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 696K USD
Research and Development Expense 74.3M USD +78.3%
General and Administrative Expense 106M USD +685%
Costs and Expenses 39.2M USD +57.6%
Operating Income (Loss) -192M USD -164%
Nonoperating Income (Expense) 10.5M USD +45.5%
Net Income (Loss) Attributable to Parent -181M USD -177%
Earnings Per Share, Basic -4 USD/shares -133%
Earnings Per Share, Diluted -4 USD/shares -133%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76.5M USD +34.1%
Marketable Securities, Current 210M USD +0.6%
Accounts Receivable, after Allowance for Credit Loss, Current 24.6M USD
Inventory, Net 2.36M USD
Assets, Current 317M USD +18.4%
Property, Plant and Equipment, Net 166K USD +774%
Operating Lease, Right-of-Use Asset 2.43M USD +808%
Intangible Assets, Net (Excluding Goodwill) 5.83M USD -25%
Other Assets, Noncurrent 83K USD 0%
Assets 332M USD +9.26%
Accounts Payable, Current 6.22M USD +67.3%
Employee-related Liabilities, Current 6.27M USD +192%
Liabilities, Current 20.9M USD +129%
Operating Lease, Liability, Noncurrent 2.25M USD
Other Liabilities, Noncurrent 271K USD
Liabilities 92.2M USD +294%
Accumulated Other Comprehensive Income (Loss), Net of Tax 85K USD
Retained Earnings (Accumulated Deficit) -501M USD -56.6%
Stockholders' Equity Attributable to Parent 240M USD -14.5%
Liabilities and Equity 332M USD +9.26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.8M USD -161%
Net Cash Provided by (Used in) Financing Activities 3.22M USD +243%
Net Cash Provided by (Used in) Investing Activities 22.9K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 50.4M shares +31.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.6M USD +94.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.5M USD +34.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 805K USD
Deferred Tax Assets, Valuation Allowance 83.5M USD +26.6%
Deferred Tax Assets, Gross 85.5M USD +26%
Operating Lease, Liability 2.92M USD +888%
Payments to Acquire Property, Plant, and Equipment 5K USD -54.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -181M USD -176%
Lessee, Operating Lease, Liability, to be Paid 3.51M USD +1037%
Property, Plant and Equipment, Gross 256K USD +153%
Operating Lease, Liability, Current 676K USD +128%
Lessee, Operating Lease, Liability, to be Paid, Year Two 861K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 751K USD +329%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 589K USD +4431%
Lessee, Operating Lease, Liability, to be Paid, Year Three 942K USD
Deferred Tax Assets, Operating Loss Carryforwards 44.3M USD -13.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.37M USD +117%
Lessee, Operating Lease, Liability, to be Paid, Year Four 665K USD
Operating Lease, Payments 103K USD +60.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 83.5M USD +26.6%
Share-based Payment Arrangement, Expense 111M USD +525%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%